Inhibition of angiogenesis and nitric oxide synthase (NOS), by embelin & vilangin using in vitro, in vivo & in Silico studies

Radhakrishnan Narayanaswamy, Majumder Shymatak, Suvro Chatterjee, Kok Wai Lam, Gnanamani Arumugam

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Purpose: In recent year's anti-angiogenesis agents have been recognized as effective drugs for the treatment of solid tumors, this prompted us to conduct the present study. Methods: The anti-angiogenic activity of dimeric form of embelin (vilangin) was evaluated using endothelial cell (in vitro) and chorioallantoic membrane (CAM) egg yolk angiogenesis model (in vivo) and in addition the docking behaviour of human nitric oxide synthases (NOS) with four different ligands was evaluated along with their putative binding sites using Discovery Studio Version 3.1 (in silico) compared with the parent compound (embelin). Results: Vilangin exhibits 50% cytotoxic at 92 ± 1 μg/ml concentration level with reference to ECV 304 endothelial cells. Both vilangin and embelin, showed inhibitory effects on wound healing, single cell migration, nitric oxide production, and endothelial ring formation at 0.1 and 1.0 μg/ml concentration level. Similarly, CAM assay also showed inhibitory effect of vilangin and embelin with respect their reduction in length, size and junctions of blood capillaries compared to untreated egg yolk. Docking studies and binding free energy calculations revealed that vilangin has maximum interaction energy (-74.6 kcal/mol) as compared to the other investigated ligands. Conclusion: The results suggest that both vilangin and embelin attenuates angiogenesis in similar manner.

Original languageEnglish
Pages (from-to)543-548
Number of pages6
JournalAdvanced Pharmaceutical Bulletin
Volume4
DOIs
Publication statusPublished - 2014

Fingerprint

Nitric Oxide Synthase
Computer Simulation
Chorioallantoic Membrane
Egg Yolk
Endothelial Cells
Ligands
Wound Healing
Cell Movement
Nitric Oxide
Binding Sites
embelin
Inhibition (Psychology)
In Vitro Techniques
Pharmaceutical Preparations
Neoplasms
Therapeutics

Keywords

  • Egg yolk angiogenesis assay
  • Embelin
  • Endothelial ring formation
  • Nitric oxide
  • Vilangin
  • Wound healing

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Inhibition of angiogenesis and nitric oxide synthase (NOS), by embelin & vilangin using in vitro, in vivo & in Silico studies. / Narayanaswamy, Radhakrishnan; Shymatak, Majumder; Chatterjee, Suvro; Lam, Kok Wai; Arumugam, Gnanamani.

In: Advanced Pharmaceutical Bulletin, Vol. 4, 2014, p. 543-548.

Research output: Contribution to journalArticle

Narayanaswamy, Radhakrishnan ; Shymatak, Majumder ; Chatterjee, Suvro ; Lam, Kok Wai ; Arumugam, Gnanamani. / Inhibition of angiogenesis and nitric oxide synthase (NOS), by embelin & vilangin using in vitro, in vivo & in Silico studies. In: Advanced Pharmaceutical Bulletin. 2014 ; Vol. 4. pp. 543-548.
@article{286012de57f64e5e866d692da88e1864,
title = "Inhibition of angiogenesis and nitric oxide synthase (NOS), by embelin & vilangin using in vitro, in vivo & in Silico studies",
abstract = "Purpose: In recent year's anti-angiogenesis agents have been recognized as effective drugs for the treatment of solid tumors, this prompted us to conduct the present study. Methods: The anti-angiogenic activity of dimeric form of embelin (vilangin) was evaluated using endothelial cell (in vitro) and chorioallantoic membrane (CAM) egg yolk angiogenesis model (in vivo) and in addition the docking behaviour of human nitric oxide synthases (NOS) with four different ligands was evaluated along with their putative binding sites using Discovery Studio Version 3.1 (in silico) compared with the parent compound (embelin). Results: Vilangin exhibits 50{\%} cytotoxic at 92 ± 1 μg/ml concentration level with reference to ECV 304 endothelial cells. Both vilangin and embelin, showed inhibitory effects on wound healing, single cell migration, nitric oxide production, and endothelial ring formation at 0.1 and 1.0 μg/ml concentration level. Similarly, CAM assay also showed inhibitory effect of vilangin and embelin with respect their reduction in length, size and junctions of blood capillaries compared to untreated egg yolk. Docking studies and binding free energy calculations revealed that vilangin has maximum interaction energy (-74.6 kcal/mol) as compared to the other investigated ligands. Conclusion: The results suggest that both vilangin and embelin attenuates angiogenesis in similar manner.",
keywords = "Egg yolk angiogenesis assay, Embelin, Endothelial ring formation, Nitric oxide, Vilangin, Wound healing",
author = "Radhakrishnan Narayanaswamy and Majumder Shymatak and Suvro Chatterjee and Lam, {Kok Wai} and Gnanamani Arumugam",
year = "2014",
doi = "10.5681/apb.2014.080",
language = "English",
volume = "4",
pages = "543--548",
journal = "Advanced Pharmaceutical Bulletin",
issn = "2228-5881",
publisher = "Tabriz University of Medical Sciences, Faculty of Pharmacy",

}

TY - JOUR

T1 - Inhibition of angiogenesis and nitric oxide synthase (NOS), by embelin & vilangin using in vitro, in vivo & in Silico studies

AU - Narayanaswamy, Radhakrishnan

AU - Shymatak, Majumder

AU - Chatterjee, Suvro

AU - Lam, Kok Wai

AU - Arumugam, Gnanamani

PY - 2014

Y1 - 2014

N2 - Purpose: In recent year's anti-angiogenesis agents have been recognized as effective drugs for the treatment of solid tumors, this prompted us to conduct the present study. Methods: The anti-angiogenic activity of dimeric form of embelin (vilangin) was evaluated using endothelial cell (in vitro) and chorioallantoic membrane (CAM) egg yolk angiogenesis model (in vivo) and in addition the docking behaviour of human nitric oxide synthases (NOS) with four different ligands was evaluated along with their putative binding sites using Discovery Studio Version 3.1 (in silico) compared with the parent compound (embelin). Results: Vilangin exhibits 50% cytotoxic at 92 ± 1 μg/ml concentration level with reference to ECV 304 endothelial cells. Both vilangin and embelin, showed inhibitory effects on wound healing, single cell migration, nitric oxide production, and endothelial ring formation at 0.1 and 1.0 μg/ml concentration level. Similarly, CAM assay also showed inhibitory effect of vilangin and embelin with respect their reduction in length, size and junctions of blood capillaries compared to untreated egg yolk. Docking studies and binding free energy calculations revealed that vilangin has maximum interaction energy (-74.6 kcal/mol) as compared to the other investigated ligands. Conclusion: The results suggest that both vilangin and embelin attenuates angiogenesis in similar manner.

AB - Purpose: In recent year's anti-angiogenesis agents have been recognized as effective drugs for the treatment of solid tumors, this prompted us to conduct the present study. Methods: The anti-angiogenic activity of dimeric form of embelin (vilangin) was evaluated using endothelial cell (in vitro) and chorioallantoic membrane (CAM) egg yolk angiogenesis model (in vivo) and in addition the docking behaviour of human nitric oxide synthases (NOS) with four different ligands was evaluated along with their putative binding sites using Discovery Studio Version 3.1 (in silico) compared with the parent compound (embelin). Results: Vilangin exhibits 50% cytotoxic at 92 ± 1 μg/ml concentration level with reference to ECV 304 endothelial cells. Both vilangin and embelin, showed inhibitory effects on wound healing, single cell migration, nitric oxide production, and endothelial ring formation at 0.1 and 1.0 μg/ml concentration level. Similarly, CAM assay also showed inhibitory effect of vilangin and embelin with respect their reduction in length, size and junctions of blood capillaries compared to untreated egg yolk. Docking studies and binding free energy calculations revealed that vilangin has maximum interaction energy (-74.6 kcal/mol) as compared to the other investigated ligands. Conclusion: The results suggest that both vilangin and embelin attenuates angiogenesis in similar manner.

KW - Egg yolk angiogenesis assay

KW - Embelin

KW - Endothelial ring formation

KW - Nitric oxide

KW - Vilangin

KW - Wound healing

UR - http://www.scopus.com/inward/record.url?scp=84921939400&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84921939400&partnerID=8YFLogxK

U2 - 10.5681/apb.2014.080

DO - 10.5681/apb.2014.080

M3 - Article

AN - SCOPUS:84921939400

VL - 4

SP - 543

EP - 548

JO - Advanced Pharmaceutical Bulletin

JF - Advanced Pharmaceutical Bulletin

SN - 2228-5881

ER -